So far, the European QP Association has been led by four industry representatives and two authority representatives. Now the Board has decided on some extensions on both sides and therefore nominated two new members: Dr Ulrich Kissel from Roche in Germany will strengthen the industry side of the Board as a nominated member, Edit Szőcs from the Hungarian National Institute of Pharmacy (NIP) will bring in her expertise from an authority’s perspective.
Dr Kissel, a German pharmacist, has more than 15 years of experience in the industry and covered a variety of roles in quality control and quality assurance as well as strategic logistics and product and technology strategy in manufacturing. Edit Szőcs, a GMP Inspector at NIP with over 10 years of QA experience in the pharmaceutical industry, gained her expertise in manufacturing, testing and packaging of various pharmaceutical dosage forms in Canada.
Further changes refer to QP Association’s Working Group “Investigational Medicinal Products”. The group has been part of the European QP Association for a couple of years already, and many of you also know its workshops at the annual QP Forums.
Now Dr Annemiek Stijnen and Martine Tratsaert, who initiated the Working Group and have been leading it since its foundation, will be joined by Dr Susanne Ding from Boehringer Ingelheim Pharma, Germany, and Philippe Van der Hofstadt from B&C Group in Belgium.
Some of you may already know Dr Ding from previous IMP workshops. As Qualified Person for IMPs at Boehringer Ingelheim Pharma she has been in charge of releasing clinic samples for the use in clinical studies worldwide since 2005. Philippe Van der Hofstadt started B&C Group in 1999. Today, he is CEO of the European niche packaging & logistics company dedicated to clinical research that is now active on a global scale.